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Small cell lung cancer (SCLC) has a 5-year survival rate of <7%. Rapid emergence of acquired
resistance to standard platinum-etoposide chemotherapy is common and improved therapies
are required for this recalcitrant tumour. We exploit six paired pre-treatment and post-
chemotherapy circulating tumour cell patient-derived explant (CDX) models from donors
with extensive stage SCLC to investigate changes at disease progression after chemotherapy.
Soluble guanylate cyclase (sGC) is recurrently upregulated in post-chemotherapy progres-
sion CDX models, which correlates with acquired chemoresistance. Expression and activation
of sGC is regulated by Notch and nitric oxide (NO) signalling with downstream activation of
protein kinase G. Genetic targeting of sGC or pharmacological inhibition of NO synthase re-
sensitizes a chemoresistant CDX progression model in vivo, revealing this pathway as a
mediator of chemoresistance and potential vulnerability of relapsed SCLC.
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Small cell lung cancer (SCLC) is an aggressive neuroendo-crine tumour accounting for ~250,000 deaths each year1.Poor prognosis is attributed to diagnosis of most patients
with metastatic disease and typically rapid disease relapse within
<1 year of diagnosis, usually after an initial response to platinum-
etoposide doublet chemotherapy alone2 or, more recently, in
combination with immune checkpoint inhibitors3. The majority
of clinical trials of targeted therapies for SCLC patients have
failed, where this heterogeneous disease is treated uniformly in
the absence of predictive biomarkers.
A major barrier to discovery of effective therapies that can be
implemented after first-line chemotherapy fails is an insufficient
understanding of what drives the rapid acquisition of chemore-
sistance despite initial chemosensitivity. The paucity of tumour
biopsies at disease progression and consequently of patient-
derived preclinical models that faithfully represent the biology of
the patient’s progressing tumour has hampered research with
some notable exceptions. Profiling of 12 paired patients’ tumour
samples at diagnosis and relapse identified acquired mutations in
Wnt-pathway genes4 and patient-derived xenograft (PDX) stu-
dies where chemoresistance was generated by repeated treatment
of mice with chemotherapy led to the discovery of schlafen family
member 11 (SLFN11) and enhancer of zeste homology 2 (EZH2)
as acquired chemoresistance mediators5. Research on genetically
engineered mouse models (GEMMs) and PDX reported increased
MYC expression during disease progression6,7.
A recent consensus report defined four subtypes of SCLC based
on transcription factor (TF) expression: two neuroendocrine (NE)
subtypes expressing TFs achaete-scute complex homolog-like 1
(ASCL1) and neurogenic differentiation factor 1 (NEUROD1), and
two non-neuroendocrine (Non-NE) subtypes expressing yes-
associated protein 1 (YAP1) and POU class 2 homeobox 3
(POU2F3)8,9. We subsequently reported an additional tran-
scriptionally distinct NE subtype based on the expression of atonal
BHLH transcription factor 1 (ATOH1)10. The importance of inter-
and intra-tumoural heterogeneity (ITH) as a mechanism of
acquired chemoresistance in SCLC11 has been suggested, but the
precise relationships between the subtypes and chemoresistance
remain unclear, though several studies demonstrate that in vitro,
Non-NE cells are more chemoresistant than NE cells9,12.
In 2014, we described a different approach to generate patient-
faithful preclinical mouse models exploiting the relatively prevalent
circulating tumour cells (CTCs) in patients with SCLC13. These
models, which we termed CDX, mirror the donor patients’ response
to chemotherapy and offer the opportunity to collect blood samples
before and after drug-resistant relapse to generate longitudinal
models of clinically acquired drug resistance14. We subsequently
described short-term cultures from disaggregated CDX tumours that
could be genetically modified, enabling experiments to validate
candidate genes responsible for acquired drug resistance15. In the
current study, we examined models derived before an SCLC patient’s
treatment and again after their treatment at disease progression from
six individual patients10. We found that both subunits of a soluble
guanylate cyclase (sGC), a protein important for sensing nitric oxide
(NO), were recurrently upregulated in disease progression vs. baseline
CDX models. This upregulation correlated with acquired chemore-
sistance of CDX in vivo and genetic reduction of sGC levels or
pharmacological inhibition of sGC activity with a nitric oxide syn-
thase (NOS) inhibitor re-sensitized a progression CDX model to
cisplatin/etoposide in vivo. These data implicate the sGC signalling
pathway as a potentially targetable vulnerability of relapsing SCLC.
Results
Genomic characterization of clinical resistance models. To
enhance understanding of SCLC acquired drug resistance, one
major ambition of the NCI Recalcitrant Cancer Act (2012) was
generation of models derived from paired biopsies obtained from
patients with SCLC prior to therapy and again after disease
progression16. The clear advantage of the CDX approach to
longitudinal models is that only a routine 10 ml blood draw
rather than an invasive biopsy is required. We derived paired pre-
treatment and post-progression CDX models from six patients
and performed whole-exome sequencing (WES) and RNA-
sequencing (RNA-seq) (Fig. 1a and ref. 10). All six patients had
an initial partial or stable response to their chemotherapy (Sup-
plementary Table 1) followed by disease progression <1 year later,
typifying the aggressive course of this disease10. Our paired CDX
models represented ASCL1 (CDX3/3P, CDX18/18P, CDX20/20P,
CDX42/42P), NEUROD1 (CDX8/8P) and ATOH1 (CDX17/17P)
subtypes of SCLC10. Previous publications studying acquired
chemoresistance in SCLC have described both genomic
alterations4 and changes in the transcriptome5–7,11 as drivers for
acquired chemoresistance. Thus, our initial attention focused on
genomic changes acquired through SCLC progression by per-
forming WES of the paired models. Our analysis identified typical
SCLC-associated mutations17 with TP53 and RB1 the most fre-
quently mutated genes in our baseline and progression models
(Fig. 1b). Of note, while we did not detect TP53 and RB1
mutations in CDX models 18 and 20 using a pipeline reporting
only somatic mutations, we did subsequently identify germline
mutations in their donors (missense mutations for TP53 in
CDX18/18P and CDX20/20P donors and nonsense RB1 muta-
tions for the CDX20/CDX20P donor). Similar to Gardner et al.5,
mutations were conserved through acquisition of chemoresis-
tance in the majority of cases across the paired CDX models. To
explore the likely identity of passenger vs. driver mutations, we
sought recurrently acquired mutations shared between the pro-
gression models (Fig. 1c). We detected only three mutations that
were shared between multiple progression models: F-box protein
10 (FBXO10), cilia and flagella associated protein 47 (CFAP47)
and dysferlin (DYSF), all mutations predicted to be passenger
mutations18. We also assessed the number of shared and private
mutations between each individual patient’s baseline and pro-
gression models to explore further their potential as mechanisms
of acquired chemoresistance (Supplementary Fig. 1a).
The majority of mutations were shared between a patient’s
baseline and progression models; however, there was a trend
(p= 0.06) of increased private mutations in progression models
implicating acquisition of mutations through either SCLC
progression or a mutagenic effect associated with exposure to
chemotherapy. Next, we examined whether mutational signatures
changed between individual baseline and progression models
(Supplementary Fig. 1b, c). As expected, the most frequent
mutational signature was signature 4, associated with C>A
mutations and tobacco smoking reflecting the patients’ smoking
histories. One exception was CDX models derived from patient
20, which displayed low signature 4 mutations. Clinical records
revealed that this patient received a sibling allogenic stem cell
transplant for the treatment of acute myeloid leukaemia (AML),
which could explain the low smoking related signature. Muta-
tional signatures were broadly conserved from baseline to
progression. We also addressed whether there were changes in
chromosomal instability during disease progression by analysing
copy number (CN) changes between baseline and progression
models (Fig. 1d). Consistent with our previous study of
longitudinal sampling and analysis of CTCs19, we did not
identify recurrent global changes between CN profiles of
progression and baseline models. In conclusion, these results
are concordant with those of others5–7,11, indicating that genomic
alterations alone are unlikely to account fully for emergence of
acquired resistance in our progression models. We refocused our
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-26823-6
2 NATURE COMMUNICATIONS |         (2021) 12:6652 | https://doi.org/10.1038/s41467-021-26823-6 | www.nature.com/naturecommunications
studies to investigate changes in the transcriptomes of pre- and
post-chemotherapy CDX models.
sGCs are upregulated during disease progression and correlate
with acquired rather than inherent chemoresistance in SCLC.
Previous studies suggested that acquired chemoresistance in
SCLC can be driven through acquisition of transcriptional
changes rather than emergence of recurrent mutations5,19.
Principal component analysis and analysis of inter-sample simi-
larity of RNA-seq data from the six paired CDX models revealed
clustering of individual pairs, confirming their origin from the
same patient and that the transcriptomes of progression models
more closely resemble their baseline counterpart rather than
other progression models (Supplementary Fig. 2a, b). First, we
examined previously reported mechanisms of acquired che-
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RNA-DNA helicase SLFN11 (ref. 5) was observed in CDX17P
(p= 0.045); however, this was not observed in any other CDX
pair (Supplementary Fig. 2c). The previously reported upregula-
tion of Wnt-pathway genes at disease progression4 was not
observed in any of the progression CDX (Supplementary Fig. 2d).
Next, we examined genes recurrently upregulated in progres-
sion compared to pre-treatment CDX. Gene set enrichment
analysis of pathways recurrently up- and downregulated in our
progression models identified cell cycle and ribosome biogenesis
pathways as some of the most upregulated pathways, essential for
sustaining tumour growth and proliferation (Supplementary
Fig. 2d). Both subunits of an sGC, guanylate cyclase soluble
subunit alpha-1 (GUCY1A1) and beta-1 (GUCY1B1), essential
components of the nitric oxide (NO) signalling pathway, were the
most significantly recurrently upregulated genes in our post-
chemotherapy disease progression models (p < 0.001, Fig. 2a,
Supplementary Data 1). This was not due to amplification of
GUCY1A1 or GUCY1B1 according to our matched WES data
(Supplementary Fig. 2g). sGCs are the primary molecular sensors
of NO with a key role in NO signalling to regulate several
physiological processes20. Of note, co-operation of phosphatidy-
linositol 3-kinase (PI3K)/AKT, Notch, and NO signalling has
been reported during tumourigenesis in a Drosophila eye cancer
model21 and NO can have both pro- and anti-tumourigenic
effects, depending on NO levels and cancer types22,23. Further-
more, Notch signalling contributes to an NE to Non-NE
phenotypic switch, the latter displaying relatively decreased
chemosensitivity12,24. These results prompted our investigation
of the role of NO signalling and sGCs in SCLC progression. We
focused our initial studies on GUCY1B1 as opposed to
GUCY1A1, since the former contains the NO-sensing H-NOX
domain essential for activation of the protein25. First, we
confirmed the upregulation of GUCY1B1 protein expression in
CDX8P, CDX17P, CDX18P and CDX20P using immunohisto-
chemistry (IHC) and western blot (Fig. 2b, c and Supplementary
Fig. 2e). Next, we asked whether an increase in GUCY1B1 protein
expression correlated with acquired chemoresistance in our CDX
models. Comparison of CDX in vivo chemoresponse to
GUCY1B1 expression revealed a trend for progression CDX
models with upregulated GUCY1B1 expression responding less
well to chemotherapy (Fig. 2d, r2= 0.462, p= 0.137).
When we assessed GUCY1B1 gene expression across a wider
panel of baseline CDX models (derived from patients before their
treatment), there was no correlation between GUCY1B1 expres-
sion and the subsequent chemotherapy response of patient
donors, suggesting that pre-treatment sGC expression levels do
not signpost inherent, chemorefractory disease (Fig. 2e).
To study the relationship between GUCY1B1 and inherent
chemoresistance further and to determine whether GUCY1B1
expression is associated with disease stage and clinical outcomes
of SCLC patients, we examined GUCY1B1 expression by IHC
across a tumour microarray (TMA) generated from 54 treatment-
naive patients (Supplementary Fig. 2f). In evaluable patients,
GUCY1B1 expression was not associated with disease stage
(p= 0.124), although there were relatively few tumours from
extensive stage patients represented on the TMA (7 vs. 37, Fig. 2f)
reflecting the challenge of obtaining tumour tissue from extensive
stage patients. There was no significant difference in GUCY1B1
expression between the 26 patients who initially responded to
chemotherapy and the eight patients who did not (p= 0.571)
(Fig. 2g). Furthermore, GUCY1B1 expression in pre-treatment
SCLC was not associated with survival (HR [95% CI]= 1.02
[0.98, 1.05], p= 0.438) in this exploratory dataset of the 33 cases
with available outcome data, using IHC scores dichotomized at a
score of 12 as the cut-point (Fig. 2h and see 'Methods'). Our
results suggest that sGCs are upregulated during SCLC progres-
sion and that GUCY1B1 upregulation is a mechanism of
acquired, as opposed to inherent, chemoresistance.
Regulation of sGC subunit expression by Notch signalling in
SCLC. The expression of both sGC subunits is regulated by Notch
signalling in human endocardial cells26 and NO synthase (NOS)
fuels tumourigenesis by activated Notch in a Drosophila eye
cancer model21. Upon binding of NO, sGC catalyses the con-
version of guanosine triphosphate (GTP) to the second messenger
cyclic guanosine monophosphate (cGMP), where it mediates a
variety of downstream effects (Fig. 3a and ref. 20). We previously
reported the upregulation of Notch receptors in four out of six
progression pairs10. Furthermore, two negative regulators of
Notch signalling, BEN domain containing 6 (BEND6)27 and
delta-like 1 homolog (DLK1)28 were downregulated in the CDX
progression models (twofold and threefold, respectively,
p < 0.001, Supplementary Data 1) consistent with elevated Notch
pathway activity, so we asked whether Notch could regulate sGC
subunit expression in SCLC. A panel of human SCLC cell lines
was assessed for GUCY1B1 expression levels to select those
appropriate for pathway analysis and function testing studies
(Fig. 3b). To determine whether GUCY-expression was Notch-
dependent, we treated Non-NE H196 cells with the γ-secretase
inhibitors DAPT and DBZ. DAPT and DBZ treatment inhibited
Notch activity, measured by a decrease in the Notch target
gene hes related family bHLH transcription factor with YRPW
motif 1 (HEY1) (p < 0.001) and concomitantly led to reduction in
sGC subunit transcripts (GUCY1B1 p < 0.001, GUCY1A1
p= 0.009) (Fig. 3c and Supplementary Fig. 3a). DAPT and DBZ
also reduced protein expression of both the Notch target hes
family bHLH transcription factor 1 (HES1) (p= 0.099) and
GUCY1B1 (p= 0.078) (Fig. 3d and Supplementary Fig. 3b). In
order to confirm the impact of pharmacological inhibition of
Notch signalling on downstream effectors of the pathway, we
downregulated Notch1 genetically using CRISPR. Down-
regulation of Notch1 expression reduced expression of the Notch
target gene HES1 as well as the expression of GUCY1B1 con-
sistent with the effects of DAPT and DBZ (Fig. 3e).
To determine whether Notch activation is sufficient to induce
sGC expression, the Notch1 intracellular domain (N1ICD) was
overexpressed in Non-NE H1048 cells which have low basal levels of
GUCY1B1. Overexpression of N1ICD significantly induced Notch
Fig. 1 Genomic characterization of clinical resistance models. a Strategy to generate paired models of acquired chemoresistance. CTCs were isolated
from SCLC patients pre-treatment and at post-chemotherapy disease progression and CDX models were generated. b The most frequently mutated genes
are shown for the CDX baseline and progression pairs from WES. Presence of a particular mutation is colour coded by the mutation type. The top panel
represents the number of genes where at least one mutation was found, and the right panel shows the number (and percentage) of models with mutations
detected for a gene. c Number of genes with acquired mutations in CDX progression models. Bars on the top panel show the number of genes with
acquired mutations. Lines with solid circles on the bottom panel below each bar represent the CDX models that share the acquired mutations. The shared
acquired mutations are F-box protein 10 (FBXO10), cilia, and flagella-associated protein 47 (CFAP47) and dysferlin (DYSF). d Copy number (CN) changes in
chromosomes of baseline and progression CDX models. Copy numbers were estimated from the baseline and progression tumour samples with respect to
their germline samples from WES data. *Value in chromosome 1 of patient 17 goes beyond the y-axis limit. See also Supplementary Fig. 1.
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signalling, shown by an increase in HES1 (p < 0.001) and GUCY1B1
(p= 0.005) expression (Fig. 3f). We sought to confirm and extend
these results obtained from established cell lines in CDX ex vivo
cultures, generated by disaggregation of CDX tumours, and short-
term culture of derived human cells15. Endogenous Notch pathway
signalling promotes an NE to Non-NE fate switch in a SCLC
GEMM12. CDX17 and CDX17P ex vivo cultures of NE and Non-
NE cell subpopulations were generated by separating floating cell
aggregates and adherent cells, respectively, and subpopulations
confirmed by the expression of the NE marker SYP9,29. As expected,
GUCY1B1 expression was elevated in CDX17P compared to
CDX17 and GUCY1B1 expression was higher in the Non-NE cell
subpopulation in both models (Fig. 3g). Treatment of CDX17P
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and to a lesser extent GUCY1B1 (p= 0.055) expression consistent
with reduced Notch signalling (Fig. 3h and Supplementary Fig. 3c).
Overexpression of N1ICD in CDX17P NE cells led to upregulation
of GUCY1A1 (p= 0.005) without a change in GUCY1B1 (p= 0.370)
(Fig. 3i). Furthermore, by performing a co-immunofluorescence
assay on NE and Non-NE cells from CDX17 and CDX17P, we
confirmed upregulation of Notch signalling in Non-NE cells (HES1
expression) concomitant with an upregulation of GUCY1B1
expression (Supplementary Fig. 3d, e). In order to address whether
the sGC subunits are Notch target genes, we investigated binding of
Notch1 to previously reported RBPJ-binding sites in the GUCY1A1
and GUCY1B1 promoter26 in H1048 cells overexpressing N1ICD by
performing chromatin immunoprecipitation (ChIP) followed by
qPCR (Fig. 3j). As a positive control, we demonstrated N1ICD
binding to a region in the HES1 promoter (p= 0.001). Our data
indicate binding of N1ICD to promoter regions of GUCY1A1
(p= 0.034) and GUCY1B1 (p= 0.048) substantiating both sGC
subunits as direct Notch target genes.
Taken together, these studies indicate that sGC subunit
expression in SCLC is regulated by Notch signalling.
sGC signalling requires nitric oxide. To study the impact of sGC
signalling on SCLC cell fate, we reduced GUCY1B1 expression using
two different sgRNAs targeting GUCY1B1. Cells were treated with
the NO donor DETA NONOate and the impact was assessed by
phosphorylation of vasodilator-stimulated phosphoprotein (pVASP)
levels, an established biomarker of sGC pathway activation30. DETA
NONOate treatment increased VASP phosphorylation in non-
targeting (sgNTA) control cell lines, whereas this effect was atte-
nuated or completely abrogated in sgGUCY1B1-1 (sgB1-1) and
sgGUCY1B1-2 (sgB1-2) cells, respectively (Fig. 4a). To verify the
specificity of this effect, we demonstrated that the sGC-specific
activator BAY 41-2272 phenocopies the effects elicited by DETA
NONOate (Supplementary Fig. 4a). To validate these findings, we
treated wild-type (WT) cell lines with 1H-[1,2,4]oxadiazolo[4,3-a]
quinoxalin-1-one (ODQ), a NO competitive inhibitor of sGC
activity. As expected, treatment with DETA NONOate increased
sGC signalling, whereas combination of DETA NONOate with
ODQ reduced sGC pathway activation to untreated levels (Fig. 4b).
Impact of sGC signalling on SCLC cell fate and chemotherapy
responses in vitro. We focused initial efforts on studying the
impact of sGC signalling on proliferation and migration/invasion,
phenotypes previously reported as influenced via this
pathway31,32. No difference in cell numbers was observed
between sgB1-1, sgB1-2 and sgNTA cells (Supplementary
Fig. 4b). Similarly, sgB1-1 and sgB1-2 cell lines did not exhibit
any difference compared to controls in their ability to migrate or
invade towards a serum gradient (Supplementary Fig. 4c, d).
Next, control sgNTA, sgB1-1 and sgB1-2 cell lines were tested for
their response to cisplatin or etoposide after prior stimulation
with DETA NONOate. sgB1-1 and sgB1-2 cells showed negligible
change in cisplatin sensitivity but both cell lines were more
sensitive to etoposide, with sgB1-2 cells showing the greater (2.5-
fold increase) etoposide sensitivity than sgB1-1 (p < 0.001)
(Fig. 4c). These data comparing sgB1-1 and sgB1-2 cells are
consistent with pathway activation readouts; in sgB1-2 cells sGC
activation by DETA NONOate was not detected, whereas sgB1-1
cells still showed partial pathway activation (Fig. 4a). As expected,
there was no difference in chemosensitivity between sgNTA,
sgB1-1 and sgB1-2 cell lines without prior stimulation with
DETA NONOate (Supplementary Fig. 4e, f). Subsequently, we
exposed WT cell lines to DETA NONOate alone or in combi-
nation with ODQ and treated cells with etoposide. Activation of
sGC signalling with NO made cells almost eightfold more resis-
tant to etoposide compared to ODQ treated cells (p= 0.002)
(Fig. 4d, e). Combined treatment of cells with the sGC inhibitor
rescued this effect, suggesting that elevated sGC signalling causes
increased resistance to etoposide in H196 cells.
Previous studies have shown that NO can directly modify and
inactivate etoposide33,34. To evaluate this specific mechanism of
resistance, we repeated the experiment with doxorubicin, a drug
with a different chemical structure that also inhibits topoisome-
rase II35. Cells became ~threefold more resistant to doxorubicin
after treatment with NO, an effect that was rescued by treatment
with ODQ (Fig. 4f, g), suggesting that etoposide resistance is
mediated through increased sGC signalling rather than direct
effects of NO on the etoposide molecule.
sGC signalling via PKG reduces response to etoposide in vitro.
PKG is one of the major downstream effectors of sGC pathway
activation36. PKG activation in vitro elicits chemoresistance in
ovarian cancer22 and in non-small cell lung cancer (NSCLC)37.
Therefore, we hypothesized that sGC pathway activation could
mediate drug resistance via PKG. To test this hypothesis, we
treated WT cell lines either with DETA NONOate alone or in
combination with a selective PKG inhibitor. As expected, treat-
ment with DETA NONOate alone increased sGC signalling and
PKG-dependent VASP phosphorylation, whereas combination
with the PKG inhibitor reduced this effect (Fig. 4h). Con-
cordantly, treatment with the PKG inhibitor reversed NO-
dependent etoposide and doxorubicin resistance (Fig. 4i–l), sug-
gesting that sGC pathway activation increases etoposide and
doxorubicin resistance via PKG activation.
Fig. 2 sGCs are upregulated during disease progression and correlate with acquired rather than inherent chemoresistance in SCLC. a RNA-seq of six
CDX progression models showing recurrent differentially expressed genes. Volcano plot indicates recurrent significantly (padj < 0.05) upregulated
(log2FC > 1) and downregulated (log2FC <−1) genes in six progression models vs. corresponding pre-treatment models. Genes that passed only one of
these thresholds are indicated in blue/green, p values from negative binomial distribution, calculated by DESeq2. b IHC of paired CDX tumours for
GUCY1B1 expression (brown stain). Scale bar set to 50 μm and equivalent throughout panels. Whole tumours were analysed and representative areas are
shown. Representative images from one mouse per group are shown. c Western blot for GUCY1B1 expression in paired CDX progression tumour lysates.
Blotting was performed on three animals per model (n= 3, Supplementary Fig. 2e) and a representative western blot is shown. d Correlation of change in
GUCY1B1 protein expression and change tumour volume in progression and baseline CDX models after treatment with cisplatin/etoposide. p= 0.137,
Pearson R2 value= 0.462, from linear regression. e Comparison of donor patients’ chemotherapy responses with GUCY1B1 expression (variance-stabilizing
transformation, VST) of the corresponding CDX model determined by RNA-seq. f Comparison of GUCY1B1 TMA% positive tumour and stage of disease of
treatment-naive patients. n= 37 limited and n= 7 extensive stage patients, data are represented as mean ± 95% confidence interval (CI). P values from
two-sided unpaired Student’s t-test, t= 1.570, d.f.= 42. g Comparison of GUCY1B1 % positive tumour and response of treatment-naive patients. Response
summarizes partial and complete response; no response stable and progressive disease. n= 26 response group and n= 8 no response group, data are
represented as mean ± 95% CI. P values from two-sided unpaired Student’s t-test, t= 0.573, d.f.= 32. h Survival analysis of treatment-naive SCLC patients
using dichotomized % positive tumour. Two-sided Kaplan–Meier (log rank) analysis was performed to estimate the median survival in each group. Wald
test= 0.85, log-rank chi square value= 0.62, d.f.= 1, and p value= 0.438. See also Supplementary Fig. 2.
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Loss of sGC signalling sensitizes CDX17P to cisplatin/etopo-
side in vivo. We sought to determine whether our in vitro findings
would be recapitulated in vivo in CDX17P, a chemoresistant pro-
gression model with elevated GUCY1B1 expression. In the absence
of a potent bioavailable sGC inhibitor for in vivo use, we adopted a
CRISPR approach to target GUCY1B1 in CDX17P ex vivo and then
tested sensitivity to the SCLC standard of care chemotherapy
regimen of combined etoposide and cisplatin in vivo (Fig. 5a). Prior
to the efficacy study, we implanted mice with CDX17P sgNTA and
sgB1-2 cells to confirm that the decreased expression was main-
tained over the time course of the efficacy experiment. GUCY1B1
expression was compared in sgB1-2 and sgNTA tumours by IHC
when they reached 700–800mm3 showing that GUCY1B1 loss was
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of the antibody for IHC) (Fig. 5b). Subsequently, sgNTA control
cells and sgB1-2 cells were implanted subcutaneously into NSG
mice and treated with either vehicle or cisplatin/etoposide. CDX17P
sgB1-2 tumours grew significantly slower than control CDX17P
sgNTA tumours (Fig. 5c), taking on average 32 days to reach
randomization volume (200mm3), 10 days slower than sgNTA
tumours (p < 0.001) (Supplementary Fig. 5a). Once randomization
volume was reached, tumours exhibited similar growth kinetics
(Supplementary Fig. 5b). Consistent with published results10, cis-
platin/etoposide did not elicit a significant response in CDX17P
sgNTA tumours; however, chemotherapy treatment slowed
CDX17P sgB1-2 tumour growth and significantly increased event-
free survival (median 9 and 15 days in vehicle and cisplatin/eto-
poside cohorts, respectively, p= 0.004) (Fig. 5d, e). Lower
GUCY1B1 protein expression in sgB1-2 tumours compared to
control sgNTA tumours at the conclusion of the study was con-
firmed by IHC and western blot of tumour lysates (Fig. 5f–h).
Staining for cleaved caspase-3 to assess apoptosis revealed a similar
induction of apoptosis upon treatment with cisplatin/etoposide in
sgNTA and sgB1-2 tumours (Supplementary Fig. 5c). Comparing
staining for phospho-histone H3 indicated a lower proliferative rate
in cisplatin/etoposide-treated sgB1-2 tumours compared to sgNTA
control tumours (p= 0.041) (Supplementary Fig. 5d).
In the absence of a potent sGC inhibitor for in vivo use, we
tested whether targeting NO production with the NOS inhibitor
L-NMMA38 could potentiate cisplatin/etoposide efficacy in
CDX17P. Treatment with cisplatin/etoposide elicited only a
minor reduction in tumour growth which was significantly
enhanced by L-NMMA co-treatment, resulting in increased
event-free survival (Fig. 5i, j, median 13 and 17 days in mice
treated with cisplatin/etoposide or cisplatin/etoposide+ L-
NMMA, respectively, p= 0.049).
Taken together, these results further establish sGC signalling as
a mediator of acquired chemotherapy resistance in SCLC.
Discussion
Most biopsies from SCLC patients are taken at the time of
diagnosis and the rarity of post relapse tumour samples is a major
obstacle to studying the rapid emergence of acquired chemore-
sistance. CTCs are a readily repeatable liquid biopsy and we took
advantage of paired pre-treatment and post-progression patient
CDX from six patients with extensive stage SCLC for this study.
RNA-seq profiling revealed recurrent upregulation of two sub-
units of an sGC in 4/6 longitudinal CDX pairs correlating with
development of chemoresistance at progression. We discovered a
link between chemoresistance and Notch/NO-mediated activa-
tion of sGC and PKG. Of note, a recent publication studying
metabolic differences between SCLC subtypes discovered a
dependency of MYC-driven SCLC on arginine, a precursor for
NO generation, and demonstrated increased dependency on
arginine in SCLC cell lines with acquired chemoresistance6. The
SCLC CDX model we used to study sGCs and acquired resistance
to SCLC standard of care chemotherapy in vivo, CDX17P,
showed upregulation of MYC compared to this donor’s baseline
model CDX1710. The aforementioned study did not link acquired
chemoresistance to NO synthesis via NOS and a relationship
between sGC and PKG signalling with development of resistance
was not investigated. Nevertheless, the combined results of
Chalishazar et al.6 and our present study warrant further inves-
tigation of the relationship between MYC, arginine dependency
and increased sGC/PKG signalling. It is also notable that MYC
cooperates with NOTCH to drive subtype switching from NE to
Non-NE12,24 and that like MYC10, GUCY1B1 is expressed in the
Non-NE subpopulation of CDX17P, suggesting that the minority
population of Non-NE cells in the tumour is responsible for
etoposide resistance during disease evolution. An outstanding
question is the source of NO within tumours. NO is typically
synthesized by endothelial cells and SCLC is a well vascularized
tumour39 as are our CDX models, implicating the vasculature as a
possible NO source. Alternatively, we have previously shown that
SCLC cells can undergo vasculogenic mimicry, a process whereby
cancer cells acquire properties of endothelial cells and form
vessel-like structures40, raising the intriguing possibility that
SCLC cells may generate NO themselves, a hypothesis warranting
further study.
NO has both pro- and anti-tumourigenic properties, most
likely dependent on cancer type and NO levels22. Low, physio-
logical levels of NO can induce angiogenesis, metastasis, tumour
growth41, cisplatin resistance22 and suppress apoptosis in various
cell types, including transformed neural cells42. The anti-
apoptotic effects were linked to stimulation of sGC and sub-
sequent activation of PKG signalling through increased levels of
cGMP43. Our in vitro studies inhibiting sGC using both chemical
and genetic methods indicate that sGC signalling mediates
resistance to the topoisomerase II inhibitors etoposide and dox-
orubicin but not to cisplatin. The majority of patients con-
tributing to the generation of our paired CDX models received a
combination of carboplatin/etoposide (CDX3/3P, CDX17/17P,
CDX18/18P, CDX42/CDX42P), including the patient donor of
CDX17P that was selected for our in vivo studies (Supplementary
Table 1). However, the patient donors of CDX8/8P and CDX20/
20P did not receive etoposide treatment. Despite this, an upre-
gulation of sGC subunits was observed in their CDX models
derived from donor patients at disease progression. Together,
these data from the six paired models suggest that evolution of
SCLC following chemotherapy (with or without etoposide) results
in resistance to topoisomerase II inhibitors and the in vivo study
in CDX17P implicates sGC signalling in this resistance. Of note,
Fig. 3 Regulation of sGC subunit expression by Notch signalling in SCLC. a Schematic of the working hypothesis. b Western blot for GUCY1B1 and
synaptophysin (SYP) expression in SCLC cell lines (n= 3). c HEY1, GUCY1B1 and GUCY1A1 mRNA expression (RT-qPCR) of DMSO- or DAPT-treated H196
cells. n= 3, data are represented as mean ± SEM. P values from two-sided unpaired Student’s t-test. HEY1 p= 0.0001, GUCY1B1 p= 0.0002. d Western
blot for GUCY1B1 and HES1 of DMSO- or DAPT-treated H196 cells. Quantification of GUCY1B1 (relative volume intensity, RVI) on the right, normalized to
histone H3. n= 3, data are represented as mean ± SEM; p values from two-sided unpaired Student’s t-test. eWestern blot for Notch1, HES1 and GUCY1B1 in
sgNTA, sgNotch1-1 and sgNotch1-2 H1048 cells (n= 3). f Western blot for N1ICD, HES1 and GUCY1B1 in empty vector control and N1ICD-overexpressing
H1048 cells. Quantification of GUCY1B1 (RVI) on the right, normalized to H3. n= 3, data are represented as mean ± SEM. P values from two-sided unpaired
Student’s t-test. N1ICD p= 0.0008, HES1 p= 0.0009. g Western blot for GUCY1B1 and SYP in CDX17 and CDX17P NE and Non-NE ex vivo cultures
(n= 2). h HEY1, GUCY1B1 and GUCY1A1 mRNA expression (RT-qPCR) of DMSO- or DAPT-treated CDX17P Non-NE cells. n= 3, data are represented as
mean ± SEM. P values from two-sided unpaired Student’s t-test. i HEY1, GUCY1B1 and GUCY1A1 mRNA expression (RT-qPCR) of empty vector control or
N1ICD-overexpressing CDX17P NE cells. n= 3, data are represented as mean ± SEM. P values from two-sided unpaired Student’s t-test. HEY1 p= 0.0005.
j Notch1 ChIP-qPCR in H1048 cells overexpressing N1ICD. qPCR of RBPJ-binding sites in the GUCY1A1 and GUCY1B1 promoter. N1ICD binding to the HES1
promoter (positive control), binding to negative control region (negative control). n= 3, data are represented as mean ± SD. P values from two-sided
unpaired Student’s t-test. See also Supplementary Fig. 3.
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previous studies on acquired resistance in SCLC found that
resistance is primarily acquired towards topoisomerase inhibitors
and not to cisplatin4,5.
In the present study, we demonstrate that resistance towards
topoisomerase inhibitors in SCLC proceeds through a sGC/PKG
axis but without reduction in apoptosis in vivo (measured at
single time-point at study conclusion). Although we did not
achieve a complete GUCY1B1 knockout in CDX17P, we were able
to significantly increase event-free survival (Fig. 5). Furthermore,
our data suggest a role of GUCY1B1 in tumour initiation, since
CDX17P sgB1-2 tumours took significantly longer to reach the
specified randomization volume compared to CDX17P sgNTA
tumours. These results raise the possibility that SCLC patients
whose tumours or CTCs exhibit high levels of GUCY1B1 may
benefit from co-targeting sGC or PKG signalling to maintain
sensitivity to etoposide. Therapeutic targeting of the sGC pathway
has been assessed in NSCLC and breast cancer models. Specific
inhibition of PKG-Iα using the inhibitor DT2 increased apoptosis
in NSCLC cell lines in vitro and in this context was synergistic
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studies and clinical trials are currently unavailable44. An alter-
native strategy could be to target NOS, which is responsible for
the generation of NO and consequently the activation of sGC and
PKG. Consistent with published data demonstrating that a NOS
inhibitor decreased KRAS-driven NSCLC tumour growth and
synergized with chemotherapy45, combination of L-NMMA with
cisplatin/etoposide delayed tumour growth and significantly
increased event-free survival in CDX17P. Although NOS inhibi-
tors have not been tested in a cancer setting, their safety and
efficacy has been tested in a clinical trial to restore mean arterial
pressure (NCT00835224), suggesting targeting NOS is a worthy
therapeutic avenue to pursue.
There are multiple, valid approaches to uncover mechanisms of
acquired resistance in SCLC. A commonly used approach is to
repeatedly treat mouse models (cell line xenografts or PDX) with
increasing drug concentrations until resistance emerges. Tran-
scriptional downregulation of SLFN11 has been identified as one
mechanism of SCLC acquired chemoresistance using this drug re-
challenge strategy to study ten PDX mouse models driven to
chemotherapy resistance5. However, comparing SLFN11 tran-
script and protein expression levels in CDX and PDX models,
Drapkin et al.7 did not identify a difference between models
derived from untreated and previously treated patients and we
could also not observe decreased SLFN11 in our progression
CDX. Another approach is to interrogate patient biospecimens to
identify alterations that correlate with acquired resistance,
although this approach is limited by scarce availability of paired
pre- and post-treatment biopsies and an inability to function test
candidate mechanisms in the clinical material. Wnt-pathway
genes4 have been implicated in SCLC resistance via WES per-
formed on paired tumour samples from 12 SCLC patients; we did
not observe these changes in our CDX study.
Our study for the first time employs transcriptomic analysis on
six paired SCLC patient-derived baseline and progression models
to uncover mechanisms of acquired chemoresistance, where in
contrast to previous mouse modelling studies, acquired resistance
occurred in the patient.
These disparities in studies on acquired resistance mechanisms
could be explained by the different model systems. Furthermore,
we did not detect GUCY1B1 and GUCY1A1 upregulation in all
six CDX progression models. We did not expect sGC signalling to
be the sole reason for chemoresistance given the high degree of
ITH in relapsed SCLC (demonstrated by single cell RNA-seq
analysis in eight CDX models11) that infers likely existence of
multiple chemoresistance mechanisms. We conclude that
whichever approach is used to discover mechanisms of acquired
chemoresistance, and we favour the paired CDX approach,
in vivo validation followed by clinical testing are the required
next steps.
In summary, by generating paired pre-treatment and post-
progression CDX models from patients with SCLC, we were able
to show a recurrent upregulation of sGCs during SCLC pro-
gression that correlated with acquired chemotherapy resistance
in vivo. sGC subunit expression was regulated by Notch signalling
and activated by NO and sGC driven chemoresistance was
mediated through PKG. This study reveals a potential vulner-
ability in relapsing SCLC. Analysis of sGC subunits in SCLC
biopsies or in readily accessed CTCs could provide a predictive
biomarker of response to sGC pathway inhibition in a disease for
which novel treatment strategies are urgently needed.
Methods
In vivo animal studies. For CDX model generation and studies testing efficacy of
cisplatin/etoposide in sgNTA and sgB1-2 CDX17P, 8–16-week-old female non-
obese diabetic (NOD) severe combined immunodeficient (SCID) interleukin-2
receptor γ-deficient (NSG) mice (Charles River) were used. For L-NMMA efficacy
studies, guided by a previous study testing L-NMMA and to increase tolerability to
the compound38, 9–11-week-old female SCID Beige mice (Envigo) were used.
Furthermore, all mice were drug/test naive, did not undergo previous procedures
and were housed in individually vented caging systems in a 12-h light/12-h dark
environment and maintained at ambient temperature and humidity, and any cell
implants and dosing were carried out in the morning on a laminar air flow bench
and mice placed back in their home cages. For CDX model generation, 10 ml of
peripheral blood was collected from SCLC patients adhering to the ethically
approved CHEMORES protocol (07/H1014/96). Information about the patients
contributing to CDX model generation can be found in Simpson et al.10. Subse-
quently, blood was processed using the RosetteSep CTC Enrichment Cocktail
(Stemcell Technologies, 15167), cells resuspended in 100 μl of a 1:1 mixture of
HITES medium (RPMI 1640 supplemented with 50 μg/ml insulin (Merck, I9278),
100 μg/ml transferrin (Merck, T8158), 100 nM hydrocortisone (Merck, H0888),
300 nM sodium selenite (Merck, S5261-100), 100 nM β-estradiol (Merck, E2758))
with Matrigel (BD Biosciences, 354234) and implanted subcutaneously into the
flank of NSG mice. When CDX tumours reached 600 mm3 (passage one, p1), they
were dissected into 3 × 3mm3 fragments, which were re-implanted into flanks of
five NSG mice (p2). Finally, p2 tumours were disaggregated and re-implanted into
five NSG mice (p3). To disaggregate tumours for CDX ex vivo cultures and to
passage p2 tumours, a gentleMACS Octo dissociator was used (Miltenyi Biotec,
130-095-937). To assess sensitivity of CDX models to treatment with cisplatin and
etoposide, 15 female NSG mice were implanted with CDX17P sgNTA or CDX17P
sgB1-2 cells with the expectation that five tumours would not grow successfully,
leaving five animals per treatment group (vehicle vs. cisplatin and etoposide). Mice
were randomized deterministically at 150–250 mm3 by assignment to vehicle or
cisplatin and etoposide treatment groups, by evenly distributing initial tumour
volume sizes. Cohort size was guided by a study by Murphy et al.46, demonstrating
that a cohort size as few as one mouse can predict treatment response. In order to
minimize potential confounding factors, tumour measurements were performed by
members of the laboratory not directly involved in the project and animals
belonging to different treatment groups were housed in separate cages. Group
allocations were known during allocation, conducting, outcome assessment and
data analysis of experiment and no animals were excluded throughout data ana-
lysis. 5 mg/kg cisplatin dosed at 5 ml/kg (Christie Pharmacy Ltd), 8 mg/kg etopo-
side dosed at 5 ml/kg (Sigma, 33419-42-0) in N-methyl-2-pyrrolidone (NMP) and
citric acid, and vehicle compound (0.9% saline solution and NMP, respectively)
was administered by intraperitoneal injection on day 1 and on days 1, 2, and 3,
respectively, or corresponding vehicle control. Mice were monitored at least twice a
week by caliper until four times initial tumour volume was reached (4× ITV) or
Fig. 4 Impact of sGC signalling on SCLC cell fate and chemotherapy responses in vitro. a Western blot for pVASP, VASP and GUCY1B1 in H196 sgNTA,
sgB1-1, sgB1-2 cells treated with NO and untreated cells (n= 3). b Western blot for pVASP and VASP of untreated, ODQ (sGC inhibitor), NO and
ODQ+NO treated H196 cells (n= 3). c Viability of H196 sgNTA, sgB1-1, sgB1-2 cells treated with NO and cisplatin or etoposide. Data as mean ± SD. IC50
of three independent replicates (n= 3). P values from two-sided unpaired Student’s t-test. sgNTA-sgB1-2 etoposide p= 0.0003. d Viability of untreated,
ODQ, NO and ODQ+NO treated H196 cells treated with etoposide. Representative data of three independent replicates are shown and IC50 values are
indicated. Data as mean ± SD. e IC50 values of d (n= 3), data as mean ± SD. P values from two-sided unpaired Student’s t-test. f Viability of untreated,
ODQ, NO and ODQ+NO treated H196 cells treated with doxorubicin. Representative data of three independent replicates are shown and IC50 values are
indicated. Data as mean ± SD. g IC50 values of f (n= 3), data as mean ± SD. P values from two-sided unpaired Student’s t-test. h Western blot for pVASP
and VASP of untreated, PKG inhibitor (PKGi), NO and PKG inhibitor+NO treated H196 cells, n= 3. i Viability of untreated, PKG inhibitor, NO and PKG
inhibitor+NO treated H196 cells treated with etoposide. Representative data of three independent replicates are shown and IC50 values are indicated.
Data as mean ± SD. j IC50 values of i (n= 3). P values from two-sided unpaired Student’s t-test. P values: PKGi-NO: 0.0001, NO-NO/PKGi: 0.0001.
k Viability of untreated, PKG inhibitor, NO, and PKG inhibitor+NO treated H196 cells treated with doxorubicin. Representative data of three independent
replicates are shown and IC50 values are indicated. Data as mean ± SD. l IC50 values of k (n= 3). P values from two-sided unpaired Student’s t-test.
P values: PKGi-NO: 0.0001, NO-NO/PKGi: 0.0001. See also Supplementary Fig. 4.
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until animal health deteriorated. To test whether targeting NO production with the
NOS inhibitor L-NMMA could potentiate cisplatin/etoposide efficacy in CDX17P,
25 SCID Beige mice were implanted subcutaneously with CDX17P with the
expectation that five mice would not grow tumours, leaving five mice per treatment
group. Mice were treated with cisplatin/etoposide as described above, 200 mg/kg L-
NMMA dosed at 5 ml/kg (Hello Bio, made up in sterile water) on days −1 to 0 and
2 to 5 and with 400 mg/kg L-NMMA dosed at 10 ml/kg on day 1 by oral gavage.
Furthermore, in order to alleviate side effects of increased mean systolic pressure
caused by treatment with L-NMMA, mice were treated with 10 mg/kg of the anti-
hypertensive amlodipine (Christie Pharmacy Ltd) by oral gavage on days of L-
NMMA treatment38. Mice for which dosing schedules could not be completed due
to a deterioration in clinical condition or body weight loss were excluded
throughout data analysis. All procedures were performed in accordance with the
Home Office Regulations (UK) and the UK Coordinating Committee on Cancer
Research guidelines, by approved protocols (Home Office Project license nos. 40-
3306/70-8252/P3ED48266), and the Cancer Research UK Manchester Institute
Animal Welfare and Ethical Review Advisory Body. CDX samples are available on



























































































































































NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-26823-6 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:6652 | https://doi.org/10.1038/s41467-021-26823-6 | www.nature.com/naturecommunications 11
Cell lines and primary cultures. SCLC cell lines NCI-H196 (source: male;
RRID:CVCL_1509), NCI-H524 (source: male; RRID:CVCL_1568), NCI-H1339
(source: female; RRID:CVCL_A472), NCI-H82 (source: male; RRID:CVCL_1591),
and NCI-H446 (source: male; RRID:CVCL_1562) were maintained in RPMI 1640
(Thermo Fisher Scientific, 21875091) supplemented with 10% FBS (Labtech, FCS-
SA) and 1× penicillin–streptomycin (Sigma-Aldrich, P0781) in a humidity con-
trolled environment (37 °C, 5% CO2). NCI-H1048 (source: female; RRID:
CVCL_1453) cell line was maintained in HITES media supplemented with 5 μM of
Y-27632 (Tocris, 1254-10) with addition of 5% FBS in a humidity controlled
environment (37 °C, 5% CO2). Cell lines were obtained from the American Type
Culture Collection (ATCC), tested negative for mycoplasma using a Venor®GeM-
qEP Mycoplasma Detection Kit (Cambio, 11-9250) run on a QuantStudio 5 Real-
Time PCR System (Thermo Fisher Scientific). Cell lines were confirmed by STR
profiling using the Promega PowerPlex 21 kit (Promega, DC8902) and analysed
using genemapper5 software and an in-house database for comparisons/matching.
To obtain primary CDX ex vivo cultures, CDX tumours were disaggregated at
passage 3 (p3) using a gentleMACS Octo dissociator. After disaggregation, cells
were grown in HITES media with addition of 2.5% FBS in a humidity controlled
environment (37 °C, 5% CO2).
SCLC TMAs. Material for the SCLC TMA was sourced through the approved
Manchester Cancer Research Centre Biobank (MCRC), Project Reference
10_FIBL_01. Patients were identified in collaboration with the clinical accredited
pathology department at Wythenshawe Hospital. A pathology review was con-
ducted by a lead pathologist on those patients who had surgically resected and
histologically confirmed SCLC (diagnosed 1993-2005) stored in the department
which were initially used for diagnostic requirements but became surplus to
diagnostic purpose. As these samples were an existing holding held prior to the
HTA commencement date of 1 September 2006, it negated the requirement for
patient consent. Specimens were processed to formalin-fixed paraffin-embedded
(FFPE) blocks in line with pathology department-approved SOPs. The TMAs were
constructed in accordance to MCRC Biobank-approved SOPs. For those patient
samples that contributed to the CDX generation, patients gave written informed
consent to donate blood samples, pre, during and post-treatment under the ethi-
cally approved ChemoRes (CHEMOtherapy RESistance) study, ethics reference—
07/H1014/96 approved by the North West Greater Manchester West Research
Ethics Committee. The focus of this study is to investigate blood borne biomarkers
for disease resistance in lung cancer patients.
RNA sequencing. RNA was extracted from RNAlater (Sigma-Aldrich, R0901)-
treated tumours derived from three independent mice per CDX model by homo-
genizing tissue in Fastprep tubes with matrix A (MP Biomedical, 116910500)
containing RLT buffer using a TissueLyserLT (Qiagen, 69980). RNA was extracted
using the RNeasy mini kit (Qiagen, 74104) and a DNase (Qiagen, 79254) digest
performed to remove leftover DNA. RNA was quantified using a Qubit™ RNA HS
Assay kit (Thermo Fisher Scientific, Q32855) and RNA with an integrity number
>8 determined using a Bioanalyzer RNA 6000 Nano assay (Agilent, 5067-1511) was
taken forward to generate libraries. Indexed PolyA libraries were prepared using
200 ng of total RNA and 14 cycles of amplification with the SureSelect Strand
Specific RNA-seq Library Preparation kit for Illumina Sequencing (Agilent,
G9691B). Library quality was checked using the Agilent Bioanalyzer. Libraries were
quantified by qPCR using the Kapa Library Quantification Kit for Illumina (Roche,
07960336001). Paired-end 2 × 75 bp sequencing was carried out by clustering
1.8–2.0 pm of the pooled libraries on the NextSeq 500 sequencer (Illumina Inc.).
RNA-seq data were aligned to Homo sapiens GRCh38 and Mouse GRCm38
assembly (Ensembl release 99) using STAR version 2.6.1d47 as part of the nf-core
RNA-seq pipeline48. These data were filtered using the bamcmp algorithm version
2.0 (ref. 49) to remove any mouse contamination reads. The counts matrix was
generated using the filtered reads and the Rsubread package version 2.0.1. Dif-
ferential expression analysis was conducted using DESeq2 (version 1.26.0)50 and
model matrix accounted for paired testing. The log2 fold change values were
shrunk via the apeglm algorithm version 1.12.0 (ref. 51) within DESeq2, and vol-
cano plots generated using Enhanced Volcano version 1.8.0 (ref. 52). Gene set
enrichment analysis was performed using generally applicable gene set enrichment
for pathway analysis (GAGE) (version 2.36)53. Sample similarity (Supplementary
Fig. 2b) is based on a Euclidian distance metric between VST normalized gene
expression profiles across all samples and clustered using the complete linkage
estimator.
Whole-exome sequencing. Genomic DNA was extracted from flash-frozen CDX
tumours using the DNeasy Blood and Tissue kit (Qiagen, 69504) by incubating
tissue overnight (O/N) in buffer ATL with proteinase K at 56 ˚C. Genomic DNA
was quantified using a Qubit™ dsDNA HS Assay Kit (Thermo Fisher Scientific,
Q32854) and run on the Agilent Tapestation Genomic DNA assay (Agilent, 5067-
5365). Genomic DNA was sheared on the Bioruptor Pico sonication system
(Diagenode, B01080010) to an average size of 150–200 bp. Libraries were prepared
using 200 ng of sheared genomic DNA, 10 cycles of pre-capture PCR and 11 cycles
of post-capture PCR, with the SureSelectXT Target Enrichment System for Illu-
mina Paired-End Sequencing (Agilent, G9641B). Low input samples were prepared
using 8–200 ng of sheared genomic DNA, 8–11 cycles of pre-capture PCR and 9
cycles of post-capture PCR, with the SureSelectXT Low Input Target Enrichment
System for Illumina Paired-End Sequencing (Agilent, G9703A). SureSelectXT
Human All Exon V6 Capture Library (Agilent, 5190-8865) was used for all sam-
ples. Library quality was checked using the Agilent Bioanalyzer. Libraries were
quantified by qPCR using the KAPA Library Quantification Kit for Illumina
(Roche, 07960336001). Paired end 2 × 101 bp sequencing was carried out by
clustering 14 pM of the pooled libraries on the HiSeq 2500 sequencer in High
Throughput mode with V3 chemistry (Illumina, Inc.). Adapter sequences were
removed from the reads using Cutadapt version 2.10 (ref. 54). Alignment of WES
data to Human reference genome GRCh38 and Mouse reference genome GRCm38
was performed using bwa-mem version 0.7.17 (ref. 55). Reads originating from
potential mouse contamination were removed using bamcmp version 2.0, an
algorithm to distinguish human and mouse reads49. Picard version 2.19.0 (ref. 56)
and GATK tools version 4.1.7 (ref. 57) was used for deduplication, realignment, and
recalibration of aligned data. Mutect2 version 4.1.7 (ref. 58) was used to call somatic
mutations (TP53 mutations were also present in the germline of patient 18 and 20
and RB1 mutations were present in the germline of patient 20) and VEP version 99
(ref. 59) was used to annotate mutation calls. CN data were generated using CNVkit
version 0.9.3 (ref. 60). Cancer mutational signatures were identified from the var-
iant calls using SigsPack in R version 1.4.0 (ref. 61).
Immunohistochemistry. IHC was performed on FFPE cores of SCLC tumours or
CDX tumours, and staining was done on 4 μm sections using recombinant anti-
GUCY1B1 antibody (Abcam, ab154841) at 6.76 µg/ml, pHH3 (Millipore, 06-570)
at 0.4 µg/ml, and cCas3 (Cell Signaling Technology, 9661) at 0.2595 µg/ml diluted
in Bond Primary Antibody Diluent (Leica Biosystems, AR9352). Heat-induced
epitope retrieval (HIER) was performed using BOND Epitope Retrieval Solution 1
(Leica Biosystems, AR9961) for 20 min and staining was carried out using the Leica
Bond Max Platform performing standard protocol F with Bond Polymer Refine
Detection (Leica Biosystems, DS9800). Scanning of the stained slides was per-
formed using a Leica SCN400. Digitally scanned slides were analysed using HALO
software v2.3 (Indica Labs).Tumour regions were defined within each sample using
a machine learning classifier. Tumour cells were detected and classified as positive
or negative based on IHC thresholds using the Area Quantification algorithm.
Expression level was quantified as percentage positive tumour within the sample.
Fig. 5 Loss of sGC signalling sensitizes CDX17P to cisplatin/etoposide in vivo. a Schematic of our strategy to study chemotherapy responses in vivo.
b IHC for GUCY1B1 expression (brown stain) of CDX17P sgNTA and sgB1-2 tumours to demonstrate maintenance of reduced GUCY1B1 expression after
in vivo passage. Scale bar set to 50 μm and equivalent throughout panels. Whole tumours were analysed and representative areas are shown. c Individual
tumour volumes of vehicle-treated mice implanted with CDX17P sgNTA or CDX17P sgB1-2 cells. Data are from five animals per experimental arm. d Mice
implanted with CDX17P sgNTA or CDX17P sgB1-2 cells were treated with a combination of 5 mg/kg cisplatin and 8mg/kg etoposide or vehicle treated.
Data from five animals per experimental arm and represented as mean ± SEM. e Kaplan–Meier survival curve comparing vehicle and cisplatin/etoposide-
treated mice until the tumour reaches 4× initial tumour volume (ITV). P values from two-sided log-rank test, chi square= 8.221, d.f.= 1. f IHC of CDX17P
sgNTA and sgB1-2 tumours for GUCY1B1 (brown stain). Scale bar set to 50 μm and equivalent throughout panels. Whole tumours were analysed and
representative areas are shown. Two representative replicates of CDX17P sgNTA and sgB1-2 tumours are shown. g Western blot for GUCY1B1 and VASP
on tumour lysates derived from two replicates per experimental arm. (−): Vehicle-arm, (C/E): cisplatin/etoposide-arm, lanes 9-12: non-randomized mice.
VASP served as a loading control. h Quantification of GUCY1B1 expression (RVI) of g, normalized to VASP expression. Six replicates for sgNTA and sgB1-2
cohorts were analysed (n= 6), data are represented as mean ± SD. P values from two-sided unpaired Student’s t-test. t= 3.367, d.f.= 10. i Mice implanted
with CDX17P were treated with a combination of cisplatin/etoposide, L-NMMA, cisplatin/etoposide+ L-NMMA or vehicle treated. Data are from three to
five animals per experimental arm and represented as mean ± SEM. j Kaplan–Meier survival curve comparing percent event-free survival of mice until the
tumour volume reaches 4× initial tumour volume (ITV). P values from two-sided log-rank test, chi square= 3.875, d.f.= 1. See also Supplementary Fig. 5.
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Co-immunofluorescence. FFPE CDX NE and Non-NE cells were cut as 4 µm
sections and stained by IHC for REST monoclonal antibody (CL0381) 1:150
(Thermo Fisher Scientific, MA5-24606, RRID:AB_2637221) and SYP (Leica Bio-
systems, PA0299) on a Leica Bond Max Platform using standard protocol F with
Bond Polymer Refine Detection kit (DS9800). GUCY1B1 and HES1 co-IF was
performed on a Leica Bond Rx Platform using the PerkinElmer Opal 4-Colour
Automation IHC Kit (NEL800001KT). Tissue sections were blocked with 3%
hydrogen peroxide (Sigma-Aldrich, H1009) for 10 min to block endogenous per-
oxidase activity, followed by 10% casein solution (Vector Laboratories, SP-5020)
for 10 min to block non-specific antibody binding. Slides were stained with
GUCY1B1 primary antibody 1:100 (Abcam, 154841) followed by DAKO envision
+ system horseradish peroxidase-coupled secondary antibody (DAKO, K4003,
RRID:AB_2630375) for 30 min, followed by incubation with OPAL Tyramide-
fluorophore (OPAL570, 1:200) for 10 min. Slides were heat-inactivated following
the tyramide-fluorophore incubation step, then blocked and probed with HES1
primary antibody 1:100 (Cell Signalling Technologies,11988, RRID:AB_2728766),
followed by DAKO envision+ system HRP-conjugated secondary antibody
(DAKO, K4003) for 30 min, followed by incubation with OPAL tyramide-
fluorophore (OPAL650, 1:200) for 10 min. Cells were stained with DAPI (1:1000)
for 15 min and slides were mounted in Molecular Probes ProLong Gold Antifade
Mountant (Thermo Fisher Scientific, P36934). Slides were digitally scanned using
an Olympus VS120.
Western blotting. Cell lysates were prepared from cell pellets or flash-frozen tissue
using the CST cell lysis buffer (Cell Signaling Technology, 9803S) in the presence of
Protease Inhibitor Cocktail (Merck, P8340) and Phosphatase Inhibitor Cocktail II
(Merck, P0044) and III (Merck, P5726). For extraction from flash-frozen CDX
tumours, tissue was homogenized in Fastprep tubes with matrix A using a Tis-
sueLyserLT in ice-cold lysis buffer. Crude lysates were clarified by centrifugation at
18,800g for 15 min in a refrigerated bench top centrifuge (Eppendorf 5417 R). A
BCA protein assay reagent kit (Thermo Fisher Scientific, 23225) was used to
determine protein concentrations and lysates resuspended in 10× NuPAGE sample
reducing agent (Thermo Fisher Scientific, NP0009) and 4× NuPAGE LDS sample
buffer (Thermo Fisher Scientific, NP0007). Protein lysates were resolved on a
NuPAGE 4–12% Bis-Tris 1.0 mm gel (Thermo Fisher Scientific, NP0322BOX)
using MOPS SDS running buffer (Thermo Fisher Scientific, NP0001). Western
blots were transferred onto PVDF membranes (Thermo Fisher Scientific,
10617354) in NuPAGE transfer buffer (Thermo Fisher Scientific, NP00061) and
membranes were blocked in 5% milk TBS blocking buffer supplemented with 0.2%
Tween (Merck, T2700) (TBST) for 1 h at room temperature with agitation. Sub-
sequently membranes were incubated with corresponding primary antibodies in
5% milk TBST overnight at 4 °C (Rabbit recombinant anti-GUCY1B1 antibody
1:1000 (Abcam, 154841), Rabbit phospho-VASP (Ser239) antibody 1:1000 (Cell
Signaling Technology, 3114, RRID:AB_2213396), Rabbit anti-VASP Antibody
1:5000 (Bethyl Laboratories, A304-769A-M, RRID:AB_2782159), Rabbit anti-
Synaptophysin antibody 1:20,000 (Abcam, ab32127, RRID:AB_2286949), Rabbit
HES1 (D6P2U) mAb 1:500 (Cell Signaling Technology, 11988, RRI-
D:AB_2728766), Rabbit GAPDH (14C10) mAb 1:5000 (Cell Signaling Technology,
2118, RRID:AB_561053), Rabbit Notch1 Antibody 1:500 (Bethyl Laboratories,
A301-895A, RRID:AB_1524102), Rabbit Histone H3 Antibody 1:5000 (Cell Sig-
naling Technology, 9715, RRID:AB_331563), Rabbit α-Tubulin Antibody 1:5000
(Cell Signaling Technology, 2144, RRID:AB_2210548), Rabbit Vinculin Antibody
1:20,000 (Abcam, ab129002, RRID:AB_11144129)) and the appropriate horse-
radish peroxidase-coupled secondary IgG 1:10,000 (Agilent, P044801-2, RRI-
D:AB_2617138) in 5% milk TBST for 1 h at room temperature. Membranes were
developed using the Supersignal West Femto Chemiluminescent Substrate
(Thermo Fisher Scientific, 34094) and the BioRad ChemiDoc XRS+ System
(BioRad, 1708265). Images were analysed using BioRad software Image Lab 3.0.1.
Unprocessed scans of blots are available in the Source Data file.
Plasmid generation and lentiviral production. To generate CRISPR/Cas9
knockout derivatives, sgRNAs were designed using CHOPCHOP v3 (ref. 62),
sgNotch1-1 sequences derived from Jiao et al.63, and sgNTA sequences were derived
from Joung et al.64 and inserted into the lentiCRISPR v2 plasmid (see Supplementary
Table 2 for sgRNA sequences). lentiCRISPR v2 was a gift from Feng Zhang (Addgene
plasmid # 52961; RRID: Addgene_52961)65. Five micrograms of lentiCRISPRv2 was
digested with FastDigest Esp3I (Thermo Fisher Scientific, FD0454) for 30min at 37 °C
in the presence of FastAP (Thermo Fisher Scientific, EF0654) and 100mM DTT
(Merck, 10197777001) and afterwards run on a 1% agarose gel, followed by gel
purification using a QIAquick Gel extraction kit (Qiagen, 28706). Oligos (100 μM)
were phosphorylated and annealed using a T4 PNK (NEB, M0201S) at the following
conditions: 37 °C for 30min and 95 °C for 5min ramping down to 25 °C at 5 °C/min.
Afterwards, ligation was performed using 50 ng of digested lentiCRISPRv2 and a 1:200
dilution of phosphorylated and annealed oligos and a Quick Ligase (NEB, M2200S).
Transformations were performed using 5 μl of ligated vector and 50 μl of NEB 5alpha
competent E. coli (High Efficiency) (NEB, C2987U). Cells were incubated on ice for
30min, followed by a heat shock at 42 °C for 30 s, incubation on ice for 5 min, 900 μl
SOC added and cells were recovered by shaking cells at 37 °C for 1 h. Afterwards, cells
were plated on 10 cm diameter agar plates containing LB and 100 μg/ml ampicillin
(Merck, A9518). To isolate the plasmids, a QIAprep Spin Miniprep Kit (Qiagen,
27106) was used. To verify successful cloning of the sgRNAs into the vector, samples
were sent for Sanger sequencing. Finally, plasmid preparation was done performing
Maxi Preps using the NucleoBond® Xtra Maxi EF kit (Macherey-Nagel, 740424.50).
pLIX-hN1ICD was a gift from Julien Sage (Addgene plasmid# 91897; RRID:
Addgene_91897). pLIX_403 was a gift from David Root (Addgene plasmid# 41395;
RRID: Addgene_41395). For lentivirus production, LentiX cells were transfected at
70% confluency in a 10 cm dish with 8.5 μg transfer plasmid, 3.4 μg pMDL, 1.7 μg
VSVG, and 3.4 μg REV using FuGENE (Promega, E2311). pMDLg/pRRE was a gift
from Didier Trono (Addgene plasmid# 12251; RRID:Addgene_12251)66; pCMV-
VSV-G was a gift from Bob Weinberg (Addgene plasmid# 8454;
RRID:Addgene_8454)67; pRSV-Rev was a gift from Didier Trono (Addgene plasmid#
12253; RRID:Addgene_12253)66. On the following day, medium was replaced with
DMEM (10% FBS, glutamine). Forty-eight hours post transfection, virus was har-
vested, centrifuged for 5 min at 300g and supernatant filtered through a 0.45 μm
acrodisc syringe filter (VWR, 514-4101). Afterwards, 5 × 106 CDX cells were infected
with 1ml of virus performing spin infection by spinning cells in a single well of a six-
well plate at 840g for 45min at 37 °C in the presence of 6 μg/ml polybrene (Merck,
TR-1003-G). Alternatively, adherent cell lines were infected in a 10 cm dish at 70%
confluency by applying 1ml of virus in the presence of polybrene. One day later, virus
containing medium was changed with fresh medium. Forty-eight hours post infection,
cells were selected daily for 7 days with puromycin (Merck, P8833).
Viability assays and inhibitors/activators. SCLC cell lines NCI-H196, NCI-
H524, NCI-H1339, NCI-H82, and NCI-H446 were maintained in RPMI 1640
(Thermo Fisher Scientific, 21875091) supplemented with 10% FBS (Labtech, FCS-
SA) and 1× penicillin–streptomycin (Sigma-Aldrich, P0781) at 37 °C, 5% CO2.
NCI-H1048 cell line was maintained in HITES media supplemented with 5 μM of
Y-27632 (Tocris, 1254-10) with addition of 5% FBS at 37 °C, 5% CO2. Cells were
treated with 100 μM DETA NONOate (Cayman Chemical, CAY82120) formulated
in water, 20 μM PKG inhibitor (Cayman Chemical, CAY15995) formulated in
DMSO, 10 μM BAY 41-2272 (Enzo Life Sciences, ALX-420-030-M005) formulated
in DMSO, 10 μM DAPT (Merck, D5942) formulated in DMSO, 5 μM DBZ (Tocris,
4489/10), 20 μM ODQ (Cayman Chemical, CAY81410) formulated in DMSO. Cell
viability assays were performed by seeding 3–10 × 104 cells in 100 μl/well in black
96-well plates (Greiner Bio-One, 655090) and drugs were added one day post
seeding at increasing concentrations to a final volume of 200 μl/well. Cell viability
was assessed by performing Cell-Titer Glo 3D assays (Promega, G9683) 7 days after
treatment with cisplatin, etoposide (Merck, E1383), and doxorubicin (Cayman
Chemical, CAY15007) in 96-well plates and analysed on a FLUOstar Omega plate
reader (BGM Labtech) and software version 5.11 R3. Cell lines were obtained from
the ATCC, tested negative for mycoplasma using a Venor®GeM-qEP Mycoplasma
Detection Kit (Cambio, 11-9250) run on a QuantStudio 5 Real-Time PCR System
(Thermo Fisher Scientific). Cell lines were confirmed by STR profiling using the
Promega PowerPlex 21 kit (Promega, DC8902) and analysed using
genemapper5 software and an in-house database for comparisons/matching.
RT-qPCR and ChIP. RNA from cultured cells was isolated using the RNeasy mini
kit and a DNase digest was performed to remove leftover DNA, and cDNA was
made using the High- Capacity cDNA Reverse Transcription kit (Thermo Fisher
Scientific, 4374967) in a ProFlex™ 2 × 96-well PCR System (Thermo Fisher Scien-
tific, 4484076) and the following conditions: 25 °C for 10 min, 37 °C for 120 min,
85 °C for 5 min. RT-qPCR was performed using the TaqMan Gene Expression
Master Mix (Thermo Fisher Scientific, 4369016) in a LightCycler® 96 Instrument
software version 1.1.0.1320 (Roche, 05815916001) and the following conditions:
50 °C for 2 min, 95 °C for 10 min, followed by 45 cycles with 95 °C for 15 s and
60 °C for 60 s. All primers were designed using the Thermo Fisher Scientific website
(GUCY1A1: Hs01015574_m1, GUCY1B1: Hs00168336_m1, HEY1:
Hs05047713_s1, B2M: Hs00187842_m1). Data were normalized to B2M. ChIP
protocol was adapted from Lee et al.68. Dual-cross-linking of cells was performed
using ChIP crosslink gold (Diagenode, C01019027) as well as formaldehyde
(Merck, F8775), followed by sonication for 30 s pulses 12 times at 4 °C. ChIP was
performed using the following antibodies: 5 µg Rabbit Notch1 antibody (Bethyl
Laboratories, A301-895A, RRID:AB_1524102), 5 µg Rabbit (DA1E) mAb IgG XP
Isotype Control (Cell Signaling Technology, 3900). RT-qPCR was performed using
the SensiFAS SYBR Hi-ROX Kit (Meridian Bioscience, BIO-92005) in a Light-
Cycler 96 Instrument (Roche, 05815916001) and the following conditions: 95 °C
for 3 min, followed by 40 cycles with 95 °C for 10 s and 62 °C for 15 s, and one cycle
with 95 °C for 10 s, 65 °C for 60 s, and with 97 °C for 1 s. Primers in GUCY1A1 and
GUCY1B1 promoter regions were derived from Chang et al.26, HES1 qPCR pri-
mers were derived from Xu et al.69, and negative control primers were adapted
from Cheng et al.70 (see Supplementary Table 2 for primer sequences).
IncuCyte proliferation assay. For proliferation assays, cells were cultured O/N in
the presence of 100 μM DETA NONOate and on the following day 4000 cells/well
seeded into 96-well plate in the presence of 100 μM DETA NONOate. Cell pro-
liferation was monitored by analysing the occupied area over a period of 7 days
using an IncuCyte ZOOM System Sartorius and software version 2016A and scans
were performed every 12 h.
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Migration/invasion assay. For migration and invasion assays, cells were serum
starved O/N in the presence of 100 μM DETA NONOate (Cayman Chemical,
CAY82120). On the following day, 50,000 cells were seeded on a Biocoat Tumor
Invasion System (Corning, 354166) or transwell inserts (Corning, 3422) in RPMI
1640 without serum in the presence of DETA NONOate and assays performed O/N.
Receiver wells contained RPMI with or without FBS supplemented with DETA
NONOate. For migration assays, individual transwells were incubated in 0.5% crystal
violet (Sigma-Aldrich, C6158) for 20min at RT, excess crystal violet washed off and
cells removed from the top of the insert. Pictures of individual transwell were taken on
a Primovert microscope (Zeiss) on a ×4 magnification, signal quantified using Fiji
(version 1.52f)71 and the fold change of migration compared to sgNTA control cells
was calculated. For invasion assays, transwells were inserted into 0.25 μg/ml calcein
AM (Corning, 354216) and incubated for 1 h at 37 °C (5% CO2), fluorescence
detected using a FLUOstar Omega plate reader (BGM Labtech) software version 5.11
R3 at 485 and 520 nm, and fold invasion to sgNTA control cells was calculated.
Additionally, images were taken on an ALS CellCelector (Automated Lab Solutions).
Quantification and statistical analysis. All tests used for statistical analysis are
detailed in the figure legends of corresponding figures and GraphPad Prism Ver-
sion 8.2.0 was used for all statistical analysis except for differential expression
analysis of RNA-seq data, WES data, and TMA survival analysis, which have been
done using R version 3.6.1, and power analysis was performed in SAS software
version 9.4. Normality was confirmed performing Shapiro–Wilk test or D’Agos-
tino-Pearson test. Survival analysis of 33 treatment-naive SCLC patients was per-
formed on % positive staining. A Cox proportional hazard regression of the %
positive tumour scores was performed, respecting the linearity and proportionality
assumptions. Prior to constructing Kaplan–Meier curves the % positive tumour
scores were dichotomized using a score of 12 as cut-point. This optimal cut-point
was calculated by maximizing the Youden index of the ROC curve and confirmed
by the maximally selected rank statistics method. Kaplan–Meier (log rank) analysis
was subsequently performed to estimate the median survival in each group. To
compare GUCY1B1 expression with stage of disease (n= 37 for limited and n= 7
for extensive stage patients) and with response of treatment (response summarizes
partial and complete response (n= 26), no response stable and progressive disease
(n= 8)), unpaired Student’s t-test was performed following Shapiro–Wilk test to
confirm normality. Power analysis was based on the Cox proportional regression
assuming complete event probability, 80% power, 0.05 significance and the
extrapolation of the results of this pilot study (HR= 1.02, sdTMA= 11.66). d.f.- and
t-values for individual experiments can be found in the Source Data file.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The RNA-seq data generated in this study have been deposited in the EMBL-EBI
ArrayExpress database under accession code E-MTAB-8465, titled ‘RNA of small cell lung
cancer circulating tumour cells derived explants’. The WES data generated in this study
have been deposited under accession code E-MTAB-10880, titled ‘Soluble guanylate
cyclase signalling mediates etoposide resistance in progressing small cell lung cancer’. The
GenBank accession codes to Human reference genome GRCh38 is GCA_000001405.15
(https://www.ncbi.nlm.nih.gov/assembly/GCF_000001405.26/) and to Mouse reference
genome GRCm38 GCA_000001635.2 (https://www.ncbi.nlm.nih.gov/assembly/
GCF_000001635.20/). Source data are provided with this paper.
Code availability
All software that was used is free and open source and details on acquiring them can be
found in the associated references. Code used to process data and generate figures in this
study has been made available on GitLab (https://gitlab.com/cruk-mi/max-schenk-gucy/).
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